[go: up one dir, main page]

MX2009004143A - Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico. - Google Patents

Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.

Info

Publication number
MX2009004143A
MX2009004143A MX2009004143A MX2009004143A MX2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A MX 2009004143 A MX2009004143 A MX 2009004143A
Authority
MX
Mexico
Prior art keywords
preventing
metabolic syndrome
water
cellulose derivatives
soluble cellulose
Prior art date
Application number
MX2009004143A
Other languages
English (en)
Inventor
Stephanie K Lynch
Maciej Turowski
Wallace H Yokoyama
Jerry R Conklin
Yun-Jeong Hong
Shao-Ching Hung
Scott A Young
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Publication of MX2009004143A publication Critical patent/MX2009004143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Los derivados de celulosa solubles en agua son útiles en métodos para prevenir o tratar síndromes metabólicos o un síntoma o una condición asociados con el síndrome metabólico en un individuo; y, en particular, para prevenir o tratar uno o más de los síntomas de: a) hipertensión; b) estado proinflamatorio o de inflamación, y c) estado protrombótico.
MX2009004143A 2006-10-20 2007-10-18 Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico. MX2009004143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338806P 2006-10-20 2006-10-20
PCT/US2007/081787 WO2008051794A2 (en) 2006-10-20 2007-10-18 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome

Publications (1)

Publication Number Publication Date
MX2009004143A true MX2009004143A (es) 2009-11-26

Family

ID=39205140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004143A MX2009004143A (es) 2006-10-20 2007-10-18 Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.

Country Status (8)

Country Link
US (2) US20110071107A1 (es)
EP (1) EP2079476B1 (es)
JP (2) JP2010506957A (es)
CN (1) CN101686994B (es)
AU (1) AU2007309226B2 (es)
CA (1) CA2666670A1 (es)
MX (1) MX2009004143A (es)
WO (1) WO2008051794A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341783A2 (en) * 2008-10-17 2011-07-13 Dow Global Technologies LLC Method of reducing absorption of trans fatty acids using water-soluble cellulose derivatives
KR20120016131A (ko) * 2009-05-08 2012-02-22 다우 글로벌 테크놀로지스 엘엘씨 경구 섭취 형태의 양이온성 하이드록시에틸셀룰로오스의 용도，및 대사 장애의 예방 및 치료
JP6007322B2 (ja) 2013-06-03 2016-10-12 信越化学工業株式会社 加熱溶融押出用組成物及びこれを用いた加熱溶融押出成型物の製造方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
CA3047168A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof
EP4203713A1 (en) * 2020-08-26 2023-07-05 Aboca S.p.A. Società Agricola New system with emerging properties for use in the treatment of metabolic syndrome

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923981A (en) * 1982-09-03 1990-05-08 Sbp, Inc. Use of parenchymal cell cellulose to improve comestibles
SE466130B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
ES2168256T3 (es) * 1991-03-01 2002-06-16 Univ Michigan Composiciones farmaceuticas y usos de eteres de celulosa con alto grado de viscosidad, hidrosolubles.
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
WO1997007689A1 (en) * 1995-08-23 1997-03-06 Moss Clive B High fibre, low calorie, dietary composition
US5766638A (en) * 1995-12-08 1998-06-16 The Dow Chemical Company Hydroxypropyl methocellulose ether compositions for reduction of serum lipid levels
GB9609171D0 (en) * 1996-05-02 1996-07-03 Orion Yhtymae Oy Antioxidant compounds
AU726408B2 (en) * 1996-12-23 2000-11-09 Dow Chemical Company, The Palatable hydroxypropyl methylcellulose ether powder with specified particle size
SE9700983D0 (sv) * 1997-03-18 1997-03-18 Ascendia Ab Stimulering, odling och preservation av pankreas- och andra celler
CA2383140C (en) * 1999-09-24 2007-12-04 Kyorin Pharmaceutical Co., Ltd. Ppar.alpha. and ppar.gamma. inhibitors
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
DE10160409A1 (de) 2001-12-10 2003-06-18 Guenther Beisel Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
AU2006214892B2 (en) 2005-02-16 2013-06-27 Kt & G Co., Ltd Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
JP2006257064A (ja) * 2005-03-16 2006-09-28 Oriza Yuka Kk 脂質吸収抑制用組成物
CA2666936A1 (en) * 2006-10-20 2008-05-02 Dow Global Technologies Inc. Method of preventing or treating metabolic syndrome

Also Published As

Publication number Publication date
JP2014037422A (ja) 2014-02-27
WO2008051794A2 (en) 2008-05-02
AU2007309226A1 (en) 2008-05-02
EP2079476B1 (en) 2014-05-21
CN101686994A (zh) 2010-03-31
CN101686994B (zh) 2013-05-01
EP2079476A2 (en) 2009-07-22
AU2007309226B2 (en) 2012-09-20
US20090093442A1 (en) 2009-04-09
WO2008051794A3 (en) 2008-06-19
CA2666670A1 (en) 2008-05-02
JP2010506957A (ja) 2010-03-04
US20110071107A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
MX2009004143A (es) Usos de derivados de celulosa solubles en agua para prevenir o tratar sindrome metabolico.
MX2010004488A (es) Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
TW200643212A (en) Gas injector and apparatus including the same
EP1850484A4 (en) EASY MATRIX BASED ON IRREGULAR LDCP, CODEC AND PRODUCTION METHOD THEREFOR
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
WO2007081878A3 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
CA118576S (en) Shredder device
WO2009058995A3 (en) Latch structure and self-adjusting pulse generator using the latch
TW200715634A (en) Stable organic devices
NO20060480L (no) Nano-baserte anordninger til bruk i en bronn
DE602007001181D1 (de) Iridiumkomplex, Carbazolderivate und Copolymer damit
WO2007112279A3 (en) Resonators
RS53586B1 (en) DERIVATION OF DECISION
ATE533947T1 (de) Einsetzausrüstung und installationsverfahren
MX2009013982A (es) Composiciones que comprenden inhibidores de triptofano hidroxilasa.
WO2008071963A3 (en) Apparatus comprising three dimensional shapes rotatably supported in on another
JP2006180460A5 (es)
WO2005077365A3 (en) Novel uses for proton pump inhibitors
UA110484C2 (ru) Целюлозний матеріал, такий як тютюн, що містить один або декілька розріджувачів диму
SI2151439T1 (sl) Nitrogeniran aromatski derivat s 6-členskim obročem in farmacevtsko sredstvo, ki obsega ta derivat
EA201000736A1 (ru) Рапс с размноженным геномом, получаемые из него составы и их применение
RU2007113430A (ru) Монисто
MXPA04003851A (es) Antipruriticos.
WO2006032011A3 (en) Combination therapy for controlled carbohydrate digestion
CA122041S (en) Freezer

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration